Week In Review: Kentucky Advances Medical Cannabis Licensing Schedule; Massachusetts Dispenses Social Equity Grants; California Advances Psychedelics Bill

LOS ANGELES–Welcome to the far too-exciting world of cannabis and psychedelics, where it’s a tale of two markets with some states doing amazingly well. And some, not so well. Let’s get to it!

Cannabis Industry Highlights

#1.Kentucky Advances Medical Cannabis Licensing Schedule:  Kentucky Governor Andy Beshear has signed House Bill 829 into law, accelerating the schedule for the state’s medical cannabis licensing to July this year from the previously set January next year. This move aims to hasten the launch of the medical cannabis industry in Kentucky.

#2. Massachusetts Dispenses Social Equity Grants to Cannabis Businesses: Governor Maura Healey of Massachusetts has allocated grants amounting to $2,350,000 to 50 cannabis social equity companies across 28 communities, utilizing funds from the state’s Cannabis Social Equity Trust Fund (CSETF). This initiative aims to support entrepreneurs from communities disproportionately affected by previous cannabis prohibition and enforcement practices.

#3. Colorado Senate Passes Stringent Digital Content Bill on Cannabis and Other Substances:The Colorado Senate recently approved SB24-158, legislation aimed at intensifying regulations on social media content concerning cannabis, psychedelics, and hemp products. This bill, met with a significant debate over free speech and the regulation of digital content, is poised to reshape how such substances are discussed online within the state.

#4.Missouri Records $125M in Cannabis Sales for March: Missouri has achieved a new milestone in cannabis sales, registering a record-breaking $124.7 million in combined medical and adult-use cannabis sales for March, as reported by the Division of Cannabis Regulation (DCR). This figure surpasses the previous records, highlighting a significant uptick in consumer spending within the state’s cannabis markets.

Psychedelic Sector Update

#1California Advances Regulated Psychedelic Therapy Bill: California’s legislative body has taken a significant step towards the formal integration of psychedelic therapy into medical practice with the Senate Business, Professions and Economic Development Committee’s recent approval of Senate Bill 1012. The bill, championed by Senator Scott Wiener of San Francisco, aims to create licensed centers where adults aged 21 and older can use substances such as psilocybin, MDMA, mescaline, and DMT under professional supervision.

#2 Cybin Inc. Secures Patent for Psychedelic-Based Depression Treatment:Cybin Inc., a biopharmaceutical company dedicated to improving mental healthcare through psychedelic-based therapies, has announced the granting of a new U.S. patent for its CYB003 program, aimed at treating Major Depressive Disorder (MDD). The patent, U.S. 11,958,807, is expected to ensure exclusivity for the company’s innovative treatments until at least 2041.

Sector-Wide Developments

– Canopy Growth’s Retail Optimization: The closure of five Canopy Growth retail locations is a strategic decision aimed at enhancing operational efficiency. This move reflects the company’s efforts to streamline operations and focus on profitable growth areas, amidst the challenges of a competitive market.

– Aurora Cannabis Enters the U.S.: Aurora’s strategic acquisition to enter the U.S. market represents a significant milestone. By taking a majority stake in a leading U.S.-based CBD company, Aurora is not only diversifying its portfolio but also positioning itself to capture growth in the world’s largest cannabis market.

– Washington’s Tax Relief for Medical Cannabis: The elimination of the 37% tax on medical cannabis in Washington State marks a progressive step towards supporting medical patients and designated providers. This legislative change is expected to make medical cannabis more accessible and affordable, potentially setting a precedent for other states to follow.

– Pure Jamaican’s Global Ambitions: The initiative by Pure Jamaican and Seven Ten Limited to export pharmaceutical-grade cannabinoid products underscores Jamaica’s emerging role in the global cannabis market. Targeting major markets like the USA and Brazil, this move highlights the country’s potential as a key exporter of cannabis and hemp products.

– Cybin’s Funding Drive for Psychedelic Development: Cybin’s aim to raise $150 million through private placement underscores the growing investor interest in the psychedelic sector. These funds are earmarked for advancing the development of psychedelic drugs, indicating strong confidence in the therapeutic and commercial potential of psychedelics.

– Indiana’s Psilocybin Research Initiative: The state’s pending legislation to advance psilocybin research for mental health treatment highlights a growing recognition of the potential benefits of psychedelic substances. This initiative, particularly focused on veterans and first responders, could pave the way for broader acceptance and utilization of psilocybin in mental health care.

To have all our content delivered right to your inbox, and never miss a beat, subscribe to our newsletter at highlycapitalized.com  Stay tuned to Highly Capitalized for more updates as the cannabis and psychedelic industries continue to shape the future at the intersection of wellness and innovation. Subscribe to our newsletter and follow us on LinkedIn.